Travere Therapeutics (TVTX) EBITDA (2011 - 2026)

Travere Therapeutics (TVTX) has 16 years of EBITDA data on file, last reported at -$36.9 million in Q1 2026.

• Quarterly EBITDA rose 13.5% year-over-year to -$36.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.1 million (up 74.89% YoY) and the FY2025 annual result came in at -$62.8 million, up 80.6% from the prior year.
• EBITDA retreated to -$36.9 million in Q1 2026, from -$32.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $24.9 million in Q3 2025 to a low of -$139.2 million in Q1 2024.
• A 5-year average of -$66.6 million and a median of -$72.0 million in 2022 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA tumbled 160.49% — and 2025, when it surged 144.4%.
• Tracing TVTX's EBITDA over 5 years: stood at -$86.7 million in 2022, then slipped by 8.69% to -$94.2 million in 2023, then soared by 35.55% to -$60.7 million in 2024, then soared by 46.61% to -$32.4 million in 2025, then dropped by 13.84% to -$36.9 million in 2026.
• The last three EBITDA figures came in at -$36.9 million (Q1 2026), -$32.4 million (Q4 2025), and $24.9 million (Q3 2025), per Business Quant data.